MARKET

DCTH

DCTH

Delcath Systems Inc
NASDAQ

Real-time Quotes | Nasdaq Last Sale

11.32
+0.04
+0.31%
Opening 13:50 06/16 EDT
OPEN
11.37
PREV CLOSE
11.29
HIGH
11.46
LOW
11.23
VOLUME
7.38K
TURNOVER
--
52 WEEK HIGH
25.18
52 WEEK LOW
8.00
MARKET CAP
73.27M
P/E (TTM)
-2.0469
1D
5D
1M
3M
1Y
5Y
5 Value Stocks To Watch In The Healthcare Sector
What Defines a Value Stock?
Benzinga · 2d ago
Delcath Systems set to join Russell Microcap Index
Delcath Systems ([[DCTH]] +10.0%) is set to join the Russell Microcap Index at the conclusion of the 2021 Russell indexes annual reconstitution effect after the US market opens on June
Seekingalpha · 06/08 17:49
Delcath Systems Set to Join Russell Microcap(R) Index
Delcath Systems, Inc. (Nasdaq: DCTH), an interventional oncology company focused on the treatment of rare primary and metastatic cancers of the liver, is set to join the Russell Microcap(R) Index at the conclusion of the 2021 Russell indexes annual reconst...
GlobeNewswire · 06/08 13:00
Delcath Systems' Hepzato Achieves 44% Best Overall Response Compared to Best Alternative Care in Eye Cancer
Benzinga · 06/07 16:21
Positive Preliminary Results from Delcath Systems' FOCUS Trial Presented at the 2021 ASCO Annual Meeting
As Previously Disclosed, the Prespecified Primary Endpoint, Objective Response Rate, Has Been Met by Exceeding the 95% CI Lower Bound Threshold for Success
GlobeNewswire · 06/07 11:49
BRIEF-Positive Preliminary Results From Delcath Systems’ Focus Trial Presented At The 2021 Asco Annual Meeting
reuters.com · 06/07 11:34
Delcath Systems to Present at LD Micro Virtual Investor Conference on June 10, 2021, at 2:30pm ET
Delcath Systems, Inc. (Nasdaq: DCTH), an interventional oncology company focused on the treatment of rare primary and metastatic cancers of the liver, today announced that management will present at:
GlobeNewswire · 06/03 13:00
Looking Into Delcath Systems's Return On Capital Employed
During Q1, Delcath Systems (NASDAQ:DCTH) brought in sales totaling $388.00 thousand. However, earnings decreased 8.25%, resulting in a loss of $6.85 million. In Q4, Delcath Systems brought in $507.00 thousand in sales but lost $7.47 million in earnings.
Benzinga · 06/02 13:53
More
Forecast
Actual (M USD)
Estimate (M USD)
Income StatementMore
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of DCTH. Analyze the recent business situations of Delcath Systems Inc through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 4 analysts

Strong Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average DCTH stock price target is 22.75 with a high estimate of 25.00 and a low estimate of 19.00.
EPS
Institutional Holdings
Institutions: 35
Institutional Holdings: 1.52M
% Owned: 23.55%
Shares Outstanding: 6.47M
TypeInstitutionsShares
Increased
6
138.92K
New
7
209.36K
Decreased
6
479.91K
Sold Out
6
359.42K
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Medical Equipment, Supplies & Distribution
-0.37%
Healthcare Equipment & Supplies
-0.38%
Key Executives
Non-Executive Chairman/Independent Director
Roger Stoll
Chief Executive Officer/Director
Gerard Michel
Chief Operating Officer/Executive Vice President
John Purpura
Chief Accounting Officer
Christine Padula
Independent Director
Gilad Aharon
Independent Director
Elizabeth Czerepak
Independent Director
Steven Salamon
Independent Director
John Sylvester
No Data
  • All
  • Financials
  • Insiders
More
About DCTH
Delcath Systems, Inc. is a late-stage clinical development company with early commercial activity in Europe focused on cancers of the liver. The Company is a specialty pharmaceutical and medical device company developing its product, Melphalan Hydrochloride for Injection for use with the Delcath Hepatic Delivery System (Melphalan/HDS). The Company's system delivers and filters melphalan hydrochloride, which is marketed as a device under the trade name Delcath Hepatic CHEMOSAT Delivery System for Melphalan (CHEMOSAT). The Company's focus is on the execution of the clinical development program (CDP) in ocular melanoma liver metastases (mOM), intrahepatic cholangiocarncinoma (ICC), hepatocellular carcinoma (HCC or primary liver) and other cancers that are metastatic to the liver.

Webull offers kinds of Delcath Systems Inc stock information, including NASDAQ:DCTH real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, DCTH stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading DCTH stock methods without spending real money on the virtual paper trading platform.